HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a global leader in IoT intelligent systems and embedded platforms, and YDCare, a medical nursing brand under New Frontier Group. Under the MOU, KLN Medical will be the sole distributor of Advantech's iWard smart ward solutions ('iWard') for the Hong Kong market. The partnership aims to synergise the three parties' expertise across smart healthcare technology, clinical application and medical supply chain management to support the digital transformation of Hong Kong's healthcare system and promote the application and development of advanced healthtech.

KLN Medical will leverage its combined strengths in healthcare supply chain management, technical capabilities and after-market support to provide medical institutions with one-stop solutions covering equipment delivery, after-sales technical support, maintenance services and system implementation co-ordination, fully supporting the smooth deployment and long-term development of iWard in Hong Kong. Through iWard's integration of patient information, clinical workflows and medical equipment and seamless connection with the existing information systems of medical institutions, together with YDCare's expertise in clinical application, the three parties will work together to help healthcare teams enhance clinical collaboration efficiency and ward operation management, drive the development of smart wards and the digitalisation of clinical workflows and create greater value for healthcare professionals and patients.

Samuel Lau, Managing Director - Integrated Logistics of KLN, said, "We are pleased to enter this tripartite partnership with Advantech and YDCare, which marks an important milestone for our expansion into the smart healthcare sector. With our professional expertise, extensive healthcare logistics network and commitment to service excellence, we will provide Hong Kong's medical institutions with efficient and reliable supply chain solutions."

Jackson Hsu, PD Head of Advantech, said, "The iWard solutions have gained recognition in multiple Asian healthcare markets including the Chinese Mainland, Thailand and Japan. We look forward to introducing this proven and reliable technology to Hong Kong in collaboration with KLN Medical and YDCare, with a view to advancing medical digitalisation. This will provide efficient operational support for frontline medical professionals and enhance the patient care experience."

Serena Xie, Founder and CEO of YDCare, said, "YDCare has been dedicated to providing home nursing care services for a decade and is one of the pioneers in home-based healthcare in Hong Kong. With our clinical perspective, professional experience and nursing best practices, we will integrate patient data with the intelligent systems. We hope this collaboration will help more medical institutions optimise nursing workflows and further improve the quality and safety of patient care."

Looking ahead, KLN Medical will continue to partner with industry leaders to deliver innovative medical technologies and promote a smarter healthcare ecosystem. 

-End-

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-rooted, global 3PL delivering customer-centric, end-to-end supply chain solutions that connect markets and power global trade, as a trusted partner to many of the top 100 global brands and Fortune Global 500 companies across a wide spectrum of industries. With a presence across 58 countries and territories, KLN offers integrated logistics, international freight forwarding, e-commerce and industrial project logistics solutions. KLN has been the global No. 1 Trans-Pacific NVOCC from Asia to the US since 2023 and ranks No. 20 among Global 3PLs (Armstrong & Associates, 2026). Listed on the Hong Kong Stock Exchange, KLN generated revenue* of over HK$56 billion in 2025 and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index. Learn more at www.kln.com

* For continuing operations only

About KLN Medical Limited

KLN Medical is dedicated to advancing healthcare in Hong Kong and Southeast Asia by delivering innovative medical technologies that improve patient outcomes. In collaboration with world-renowned partners, KLN Medical ensures that healthcare professionals have access to the latest advancements, driving excellence across the continuum of care. As a member of the KLN Group, KLN Medical focuses on the reliable distribution of high-quality medical devices and solutions. Its multidisciplinary team brings deep expertise across key areas including cardiovascular care, rehabilitation, hospital and clinic support, engineering, marketing, business development, regulatory affairs and quality assurance, customer service, and operations. Website: www.medical.kln.com

About Advantech Co., Ltd

Advantech is a global leader in IoT intelligent systems and embedded platforms, with the corporate vision of "Enabling an Intelligent Planet." To embrace the trends of edge computing and artificial intelligence, Advantech fully deploys its sector-driven strategy and focus on Edge Computing and Edge AI, targeting five key markets: Edge Intelligence Systems, Manufacturing, Energy and Utilities, iHealthcare, and iCity Services & iRetail. In the meantime, Advantech is enhancing its global presence and core competitiveness by integrating its Edge Computing hardware platform, the WISE-IoT software platform, and sector-specific Edge AI solutions with domain expertise. The integration will form an "Orchestration" model for seamless industrial chain connections, benefiting both partners and clients. Advantech is also working with business partners to co-create business ecosystems that accelerate the goal of industrial intelligence. Website: https://www.advantech.com/zh-tw

About YDCare

YDCare is the flagship home care brand of New Frontier Group. Backed by the Group's premium medical resources, YDCare continuously enhances its personalised, comprehensive, and tiered professional services to meet the diverse home care needs of both the elderly and children in China. Led by senior nursing experts and a multidisciplinary team, its Hong Kong & International business line is dedicated to extending hospital-grade safety standards and clinical workflows into the home environment. The platform delivers a one-stop service encompassing medical nursing, daily care, home rehabilitation, palliative and end-of-life care, and medical equipment rental. Notably, YDCare pioneers advanced medical technologies in Hong Kong's home settings, including Negative Pressure Wound Therapy (NPWT) and Home Parenteral Nutrition (HPN), enabling patients to recover safely in familiar surroundings while effectively reducing unnecessary hospitalisations and commutes. Website: www.ydcarehk.com

香港, 2026年7月13日 /美通社/ -- KLN Logistics Group Limited（「KLN」；股份代號0636.HK）欣然宣布，旗下醫療保健業務附屬公司KLN Medical Limited （「KLN Medical」）與全球物聯網系統及嵌入式平台領導供應商研華股份有限公司（「研華」；股份代號2395.TW）和新風天域集團旗下醫療護理品牌YDCare易得康（「易得康」）簽署三方合作備忘錄。根據合作備忘錄，KLN Medical將成為研華iWard智慧病房解決方案（「iWard」）於香港市場的獨家經銷商。是次合作旨在結合三方於智慧醫療科技、臨床應用及醫療供應鏈管理方面的專業能力，支持香港醫療體系數碼轉型，促進智慧醫療技術的應用及發展。

KLN Medical 將充分發揮其醫療供應鏈管理、專業技術及售後支援的綜合優勢，為香港醫療機構提供涵蓋設備配送、售後技術支援、維護服務及系統導入協調等一站式服務，全面支援iWard於香港市場的順利部署及長遠發展。透過iWard整合病人資訊、臨床工作流程及醫療設備，並與醫療機構現有資訊系統無縫整合，同時結合易得康在臨床應用的專業能力，三方將攜手協助醫護團隊提升臨床協作效率及病房營運管理水平，推動智慧病房建設及臨床工作流程數碼化，為醫護人員及病人創造更高價值。

KLN綜合物流總裁劉健培表示：「我們很高興與研華及易得康達成三方夥伴合作，此次合作是我們拓展智慧醫療領域的重要里程碑。憑藉專業的能力與完善的醫療物流網絡優勢，以及對卓越服務的承諾，我們將為香港醫療機構提供高效可靠的供應鏈解決方案。」

研華智慧醫療解決方案事業部負責人許全慶表示：「iWard智慧病房解決方案已應用於中國內地、泰國及日本等亞洲醫療市場並獲得肯定。我們期待將成熟可靠的技術引入香港，與KLN Medical及易得康合力促進醫療數碼化發展，為前線醫護提供高效的工作支援，同時為病人帶來更優質的護理體驗。」

易得康聯合創始人兼首席執行官謝韞之表示：「易得康深耕居家護理服務十年，更是香港居家醫療護理的先行者之一，我們將從臨床專業視角出發，結合專業經驗與護理標準，將病人數據與智能系統整合，期望這次三方合作能協助更多醫療機構優化護理流程，進一步提升護理品質及安全。」

展望未來，KLN Medical將繼續與業界領袖合作，引進創新的醫療科技，推動更智慧的醫療生態系統。

-完-

關於KLN Logistics Group Limited（股份代號0636.HK）

KLN是紮根亞洲的國際第三方物流服務供應商，致力提供以客戶為中心的端到端供應鏈解決方案，連繫各地市場，促進環球貿易，為全球眾多百強品牌及《財富》世界500強企業在不同行業所信賴的合作夥伴。KLN 的辦事處遍布全球58 個國家及地區，業務涵蓋綜合物流、國際貨運、以及電子商貿和工業項目物流等。KLN自2023年起為全球第一大亞洲至美國跨太平洋貿易航線無船承運商，以及在全球第三方物流供應商中排名第20位（Armstrong & Associates，2026年）。KLN於香港聯合交易所上市，2025 年收入*逾 560 億港元，並為恒生可持續發展企業基準指數成份股。了解更多，請瀏覽：www.kln.com  

* 僅就持續經營業務而言

關於KLN Medical Limited

KLN Medical 致力推動香港及東南亞地區的醫療發展，提供創新醫療科技，提升病人治療成效。憑藉與多個國際知名品牌的合作，KLN Medical 協助醫療專業人員掌握最新醫療技術，全面提升醫療質素。作為 KLN 集團旗下成員，KLN Medical 專注於高品質醫療器材與解決方案的穩定分銷。其多元化團隊在多個專業範疇具備深厚經驗，包括心血管護理、復康支援、醫院及診所運作、工程、行銷、市場拓展、法規事務與品質保證、客戶服務及營運管理等。網站連結：www.medical.kln.com

關於研華股份有限公司

研華為全球物聯網智能系統與嵌入式平台領導廠商，並以「智能地球的推手」作為企業品牌願景。為迎接邊緣運算與人工智慧之大趨勢，研華以Sector Driven策略全面展開佈署，並將以Edge Computing和Edge AI為核心，聚焦邊緣智能系統、智慧製造、能源與公共事業、智能醫療、智能零售與服務等五大關鍵市場，加強全球布局提升核心競爭力；整合Edge Computing邊緣硬體平台產品群、工業物聯網軟體平台WISE-IoT，再加入產業Edge AI解決方案及行業知識，重塑成產業整合應用的協同共譜之經營模式，助力夥伴客戶串接產業鏈；此外，亦積極偕同各產業夥伴「共創」產業生態圈，以加速實踐產業智能化之目標。網站連結：https://www.advantech.com/zh-tw

關於易得康

「易得康」是新風天域集團旗下的居家護理核心品牌，依托集團的優質醫療資源，持續升級個性化、全方位的分層專業服務供給體系，專注於滿足中國「一老一小」多元化的居家護理需求。其香港及國際業務品牌「YDCare」由資深護理專家領銜，匯聚多學科專業人才，致力於將醫院級安全標準與臨床流程延伸至家中。平台不僅提供醫療護理、生活照顧、居家康復、安寧療護及醫療設備租賃的一站式服務，更率先在香港居家場景中引入負壓傷口治療（NPWT）、靜脈營養治療（HPN）等前沿醫療技術，讓患者在熟悉的環境中安心康復，有效減少不必要的住院與往返醫院。網站連結：www.ydcarehk.com

Lei Jun, founder of XIAOMI-W (01810.HK), said Xiaomi Auto will enter the European market next year. Earlier reports said Xiaomi hired Dieter Lorenz, former Senior Manager of Delivery Operations for Central Europe at Tesla, Inc. (TSLA.US), in April as the company's head of European delivery and logistics.

Furthermore, Lei revealed that the new-generation SU7 became the best-selling sedan priced above RMB200,000 in June.

XIAOMI-W last stood at HKD25.92 today (13th), up 0.31%, with trading volume of 114 million shares and turnover of HKD2.986 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

SK hynix Inc. (SKHY.US) was listed on Nasdaq last Friday (10th), closing at USD168.01, 12.8% above its offering price. SK hynix Inc. CEO Kwak Noh-Jung said the global memory chip industry will face the most severe supply shortage in history in 2027. Despite the company's aggressive capacity expansion, memory demand is expected to continue exceeding the company's production capacity over the next decade.

He said that from a supply perspective, next year will be the worst year in the industry's history, as customer demand continues to grow while the company's production capacity remains limited. The US, Japan and SE Asia remain candidate locations for future wafer fabrication investments, and the company will prioritize locations capable of providing sufficient land, electricity, water resources and skilled labor at competitive manufacturing costs.
~

AASTOCKS Financial News
Website: www.aastocks.com

GUANGZHOU, China, July 10, 2026 /PRNewswire/ -- XPENG has officially started employee testing of its Robotaxi platform, marking a major milestone in the company's journey from intelligent electric vehicles to autonomous vehicles powered by Physical AI. The programme follows just eight months after XPENG first unveiled its Robotaxi initiative at XPENG AI Day 2025, reinforcing the company's rapid progress towards commercial deployment.

To mark the occasion, XPENG Chairman and CEO He Xiaopeng became the first internal passenger to complete a full end-to-end Robotaxi journey, successfully placing an order, being picked up and reaching his destination through the XPENG Robotaxi platform. The test demonstrated that the company has successfully connected the entire service chain, from ride hailing and autonomous dispatch to passenger transport and journey completion.

The employee testing programme was announced during XPENG's first company-wide Robotaxi business meeting, where He Xiaopeng outlined the strategic importance of autonomous mobility to the company's future development.

"Robotaxi represents an important step in XPENG's expansion from smart electric vehicles to robotic vehicles," said He Xiaopeng, Chairman and CEO of XPENG. "Over the next decade, Physical AI will increasingly evolve into robots. For XPENG, Robotaxi is not simply a new business, but one of the most important milestones in unlocking the real potential of Physical AI."

From Smart EVs to "Robotic Vehicles"

As autonomous driving advances from driver assistance to full autonomy, XPENG believes vehicles will increasingly become intelligent robotic platforms capable of perception, reasoning and decision-making.

Powered by XPENG's self-developed Turing AI chip, VLA2.0 AI model and proprietary infrastructure, Robotaxi represents one of the company's most complete Physical AI applications to date, bringing together its advances in intelligent vehicles, autonomous driving and embodied AI into a single platform.

Built for Global Scale

He Xiaopeng also used the meeting to outline its long-term Robotaxi strategy. Rather than operating ride-hailing fleets itself, the company intends to serve as a technology provider and ecosystem enabler - supplying the software, hardware and AI capabilities required for autonomous mobility, while working with local partners to deliver services on the ground.

Leveraging the same technology foundation underpinning both its L2 intelligent driving and L4 autonomous driving systems, XPENG's Robotaxi platform is designed for rapid deployment across different cities and markets without relying on LIDAR heavy architectures or high-definition maps.

"The second-generation VLA model's ability to generalise across different environments significantly reduces the cost and complexity of deployment," said Candice Yuan, Head of XPENG Robotaxi.

Following the launch of employee testing, XPENG plans to complete trial operations and establish regular demonstration services during 2026, using Guangzhou as a model city to develop operational experience that can be replicated globally. The company confirmed it is already exploring potential Robotaxi partnerships across Europe, the Middle East and Southeast Asia.

About XPENG

Founded in 2014, XPENG is a leading AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province. XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).

Contacts: 
Email: [email protected]
Website: https://www.xpeng.com/

TIANJIN, China, July 10, 2026 /PRNewswire/ -- Weichai Power (HKG:2338) announced that its independently developed WP15 hydrogen direct‑injection engine for heavy-duty vehicles has successfully passed the full China VI vehicle emission certification tests on July 3 at the CATARC Automotive Test Center (Tianjin) Co., Ltd. The achievement makes it the first heavy‑duty hydrogen internal combustion engine in both China and the world to comply with the country's stringent China VI emission standard.

The certification was conducted under the complete operating cycle required by China's national heavy-duty engine emission standards. Testing covered a full range of operation condition, including cold start, low‑speed idling, high‑speed full‑load, and transient variable load changes, verifying the engine's emission performance, reliability and stability in real‑world applications.

Designed for zero‑carbon heavy‑duty transportation, the WP15 adopts a hydrogen direct-injection, spark‑ignited architecture and delivers industry-leading performance. Featuring a 14.6-liter displacement, the engine produces up to 600 horsepower and 2,800 N•m of torque while achieving a maximum brake thermal efficiency of 46.8%, combining strong power, low consumption, and zero emissions with strong commercialization potential.

With over 90% component commonality with conventional engine platforms, the WP15 inherits proven advantages in load capacity, range, and environmental adaptability, reducing production, retrofitting, and maintenance costs. Furthermore, its higher tolerance for hydrogen purity also lowers end-user fuel costs and accelerates fossil fuel replacement. The engine is well-suited for long-haul trucks, mining dump trucks, port equipment, steel mill vehicles, and large hydrogen power generators, driving green upgrades across transportation and heavy equipment sectors.

With 80 years of history, Weichai has been at the forefront of hydrogen power innovation in China. Through sustained investment in research and development, the company has established an integrated innovation system spanning fundamental research, technology development, product engineering, testing and commercialization, achieving multiple breakthroughs in the key hydrogen engine technologies.

This certification represents a significant achievement in Weichai's deep commitment to independent innovation and green development. Looking ahead, the company will accelerate mass production, actively support national hydrogen demonstration projects, and continue delivering high‑performance, zero‑carbon powertrain solutions that advance industrial decarbonization and the sustainable growth of the hydrogen energy industry.

For more information about Weichai Power, please visit https://weichai.com/ and its pages on X https://x.com/WeichaiOfficial and Facebook https://www.facebook.com/WeichaiGroup.

Tashan Technology, the first global haptic simulation partner of NVIDIA Corporation (NVDA.US), recently completed a B-round financing worth several hundred million RMB.

Investors in this round included JOYSON ELEC (00699.HK), Taiping Innovation, AUX, PENGLING (300375.SZ), Lavender Hill Capital Partners (LHCP), and other industry investors. Existing shareholders DOWSTONE TECH (300409.SZ) and BeFor Capital also made additional investments.

Founded in 2017, Tashan Technology was jointly established by core teams from Tsinghua University, the University of Manchester and other global senior R&D teams. In 2025, the company completed its A3-A5 financing rounds, attracting participation from 15 leading cross-sector investors.
~

AASTOCKS Financial News
Website: www.aastocks.com

Meta Platforms, Inc. (META.US) plans to begin production of its AI chip codenamed "Iris" starting in September, Reuters, citing an internal memo, reported. The chip is Meta's fourth-generation Meta Training and Inference Accelerator (MTIA).

Meta hopes to use the chip to enhance AI performance on its Facebook and Instagram social media platforms. The memo showed that testing of the chip took only six weeks and no major issues were identified.

The chip was designed by Meta based on its own requirements, with Broadcom Inc. (AVGO.US) providing design assistance, while manufacturing is handled by Taiwan Semiconductor Manufacturing Company Ltd. (TSM.US).

For Meta, the main purpose of developing in-house chips is to supplement existing GPU resources, reduce AI infrastructure costs, and lessen dependence on NVIDIA Corporation (NVDA.US) and Advanced Micro Devices, Inc. (AMD.US).
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics Chairman Lee Jae-yong is expected to meet NVIDIA Corporation (NVDA.US) CEO Jensen Huang in the US later this month, aiming to expand cooperation in semiconductor and AI investment plans, South Korean media reported.

Lee is reportedly arranging a meeting with Huang in Silicon Valley. The increasingly close cooperative relationship between Samsung and NVIDIA is expected to become a key topic.

Initial cooperation between the two sides mainly focused on Samsung's memory chips and NVIDIA's GPUs, but has now expanded into the foundry business. Samsung is producing Groq 3 language processors for NVIDIA under contract.
~

AASTOCKS Financial News
Website: www.aastocks.com

北京2026年7月9日 /美通社/ -- 近日，AI製藥領軍企業晶泰科技（2228.HK）與代謝疾病領域龍頭甘李藥業（603087.SH）聯合共建的「AI智肽遞送實驗室」（人工智能多肽藥物設計與遞送系統研發北京市重點實驗室），獲得「北京市重點實驗室」認定並正式揭牌。這是繼去年11月雙方建立戰略夥伴關係以來的又一重要合作進展，標誌著雙方在AI賦能多肽藥物研發的領域合作步入全面深化階段，也印證了晶泰科技AI多肽開發平台PepiX™在產業端的持續轉化與規模化應用潛力。

中國科學院院士、世界科學院院士馬光輝，加拿大皇家科學院院士Andrei K. Yudin，晶泰科技聯合創始人、首席創新官賴力鵬博士，甘李藥業創始人甘忠如博士，甘李藥業董事長兼CEO陳偉博士等專家及嘉賓出席揭牌儀式。

北京市重點實驗室是北京科技創新體系的重要組成部分，承載著集聚優秀創新人才、開展高水平研究、推動關鍵技術攻關的戰略任務。此次重點實驗室成功獲批，標誌著晶泰科技源頭創新實力與工程化落地能力再次獲得權威認可。同時，晶泰科技將依托這一高能級創新載體，與戰略合作方甘李藥業、科研夥伴中國科學院過程工程研究所深度協同，加速新一代多肽藥物的研發突破與臨床轉化。

當前，受益於GLP-1類藥物的爆發式增長，多肽藥物正迎來黃金發展期，研發方向加速向多靶點、口服化、長效化等新形態演進。然而，多肽分子在體內易降解、靶向遞送效率低，以及高端遞送載體及核心制備工藝長期被海外壟斷等挑戰制約了國內多肽新藥轉化。面對上述難題，晶泰科技與甘李藥業基於已有的堅實合作基礎，聯合共建 「AI 智肽遞送實驗室」，重點圍繞代謝性慢病領域開展研究，致力於構建 「分子設計-遞送開發-臨床轉化」 的全鏈條技術平台，加速推動本土多肽新藥的研發和臨床轉化進程。

該聯合實驗室主要圍繞三大方向開展技術攻關：一是打造AI驅動的「虛擬篩選+濕實驗驗證」一體化平台，推進代謝性慢病治療多肽分子的設計與成藥性優化；二是開發新型口服遞送系統，提升多肽藥物的胃腸道穩定性、跨膜轉運效率及生物利用度；三是探索超長效遞送與緩釋制劑技術，推動給藥向更長週期延展。

晶泰科技自主研發的AI多肽藥物開發平台PepiX™，融合精準AI設計、高通量濕實驗篩選與自動化合成三大能力，構建「干實驗設計+濕實驗驗證」的高效研發閉環，將傳統多肽研發週期從數年壓縮至數月。甘李藥業作為國內代謝疾病領域的龍頭企業，擁有深厚的產業積澱與臨床轉化實力，已構建起「多肽分子設計-遞送系統開發-代謝慢病轉化」的完整能力閉環，使實驗室能夠高效完成從靶點發現到產業化的全流程驗證。雙方強強聯合，有望打通「研發-臨床-產業化」完整鏈路，加速更安全、更高效的新一代多肽藥物的臨床轉化進程，並在真實的藥物研發場景中進一步拓寬雙方的技術護城河。

目前，晶泰科技PepiX™平台已實現多賽道技術落地，正在重點佈局多款腦部遞送、眼部遞送及口服肽等高潛力多肽藥物的開發並取得多項標桿性成果。其中，PepiX™研發的食品級口服功能肽Tensotide已正式獲得美國Self-affirmed GRAS（一般認為安全）認證，可合法用於美國食品及膳食補充劑市場。依托此次獲批的「AI智肽遞送實驗室」，晶泰科技與甘李藥業將在前期成功合作的基礎上，進一步深化戰略協同，共同構建「政產學研用」深度融合的協同創新生態，加速原創多肽新藥從研發設計到產業化落地的全鏈條轉化進程，推動國產多肽創新藥物在代謝類慢病領域實現關鍵突破，為全球患者帶來更優的治療選擇。

甘李藥業董事長兼CEO陳偉表示：「實驗室由甘李藥業、晶泰科技、中科院過程工程研究所三方共同參與、優勢互補，形成了AI解題、基礎研究與產業拓展深度融合的創新模式，這正是中國生物藥從Fast Follow走向First-in-class所必需的生態融合。」

晶泰科技聯合創始人、首席創新官賴力鵬表示：「此次『AI智肽遞送實驗室』獲認定為北京市重點實驗室，標誌著晶泰科技與甘李藥業的戰略合作邁入新階段。我們期待以此實驗室為平台，充分發揮晶泰科技在AI多肽分子設計、自動化合成及高通量濕實驗篩選方面的全鏈條早期研發技術優勢，結合甘李藥業在代謝類多肽領域數十年的產業積累與卓越的臨床轉化能力，聯合攻堅長效修飾智能遞送的產業難題，推動更多具有差異化優勢的多肽新藥進入臨床。」

關於甘李藥業

甘李藥業股份有限公司（簡稱：甘李藥業，股票代碼：603087.SH）作為中國第一家掌握產業化生產重組胰島素類似物技術的高科技生物製藥企業，具備完整胰島素研發管線。

甘李藥業在中國胰島素第二次集中帶量採購中，胰島素類似物中選協議量居中選企業首位，國內市場基礎持續夯實。與此同時，公司國際化進程穩步推進，甘精胰島素注射液、賴脯胰島素注射液及門冬胰島素注射液均已獲得歐盟委員會（EC）上市批准，正穩步向全球代謝疾病領域核心參與者邁進。

立足中國，放眼全球，甘李藥業始終致力於為全球患者提供更高質量的藥品與服務。

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。